Published in Antimicrob Agents Chemother on March 01, 1982
Herpes simplex virus microneutralization: a simplification of the test. J Infect Dis (1975) 1.63
Incubation of swab materials with herpes simplex virus. J Infect Dis (1980) 1.58
Failure of neutral-red photodynamic inactivation in recurrent herpes simplex virus infections. N Engl J Med (1975) 1.43
Ineffectiveness of topical ether for the treatment of genital herpes simplex virus infection. N Engl J Med (1978) 1.16
Ineffectiveness of topical adenine arabinoside 5'-monophosphate in the treatment of recurrent herpes simplex labialis. N Engl J Med (1979) 1.07
Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun (1979) 1.05
Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice. J Infect Dis (1978) 1.04
Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. J Infect Dis (1978) 0.86
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Replication of semliki forest virus: three forms of viral RNA produced during infection. Proc Natl Acad Sci U S A (1966) 3.23
Virus myocardiopathy. Prog Med Virol (1973) 2.73
Residual pathologic changes following murine coxsackie A and B myocarditis. Am J Pathol (1969) 2.47
A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med (1994) 2.32
A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis (1975) 2.14
Inhibition of tumor growth by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.00
Bacteremia in narcotic addicts at the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. Rev Infect Dis (1986) 1.82
Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis (1983) 1.80
Molecular basis of the action of interferon. J Mol Biol (1968) 1.70
Characteristics of pneumonias caused by Escherichia coli. N Engl J Med (1967) 1.68
Incubation of swab materials with herpes simplex virus. J Infect Dis (1980) 1.58
Coxsackievirus myocarditis--with special reference to acute and chronic effects. Prog Cardiovasc Dis (1985) 1.57
Augmentation of the virulence of murine coxsackie-virus B-3 myocardiopathy by exercise. J Exp Med (1970) 1.54
Simultaneous serum and CSF antibodies in herpes simplex virus encephalitis. JAMA (1978) 1.48
The clinical spectrum of Mycoplasma pneumoniae infections. Med Clin North Am (1978) 1.46
Editorial response: microbial persistence and idiopathic dilated cardiomyopathy. Clin Infect Dis (1999) 1.45
Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med (1972) 1.44
Ribosomes: effect of interferon on their interaction with rapidly labeled cellular and viral RNA's. Science (1967) 1.44
The recognition of viral RNA by mammalian ribosomes. An effect of interferon. Biochim Biophys Acta (1968) 1.44
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst (1976) 1.42
Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med (1970) 1.42
Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery (1996) 1.39
Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J Infect Dis (1977) 1.33
Some factors affecting the interferon-induced antiviral state. Proc Soc Exp Biol Med (1967) 1.33
Effect of interferon on early interferon production. Science (1966) 1.30
Interferon action on parental Semliki forest virus ribonucleic acid. J Virol (1967) 1.28
Characteristics of nonbacteremic Pseudomonas pneumonia. Ann Intern Med (1968) 1.27
Bacteroides pneumonias. Characteristics of cases with empyema. Ann Intern Med (1968) 1.26
Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy. Rev Infect Dis (1986) 1.25
Differential sensitivity of herpes simplex virus types 1 and 2 to human interferon: antiviral effects of interferon plus 9-beta-D-arabinofuranosyladenine. J Infect Dis (1976) 1.21
Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother (1987) 1.20
An interdisciplinary method of classifying and monitoring medication errors. Am J Hosp Pharm (1985) 1.19
The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med (1996) 1.19
Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis (1977) 1.19
The effect of polyinosinic-polycytidylic acid upon graft-vs-host activity in BALB/c mice. J Immunol (1970) 1.18
Herpesvirus hominis encephalitis in Michigan. Report of thirteen cases, including six treated with idoxuridine. N Engl J Med (1970) 1.18
Pneumonias caused by gram negative bacilli. Medicine (Baltimore) (1966) 1.18
Coxsackievirus myocardiopathy. J Infect Dis (1969) 1.17
Passive hemagglutinating antibodies in cerebrospinal fluids in herpesvirus hominis encephalitis. 1. Proc Soc Exp Biol Med (1972) 1.16
Xeroradiographic, bacteriologic, and pathologic studies in experimental staphylococcus osteomyelitis. Proc Soc Exp Biol Med (1977) 1.16
Treatment of patients with pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy. Medicine (Baltimore) (1978) 1.16
Interferon and uninfected cells. Proc Soc Exp Biol Med (1966) 1.15
Hemophilus influenzae bronchopneumonia in adults. Arch Intern Med (1968) 1.14
Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet (1983) 1.14
Idoxuridine in herpes simplex virus (type 1) encephalitis. Experience with 29 cases in Michigan, 1966 to 1971. Ann Intern Med (1973) 1.12
Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet (1976) 1.10
Interferon: lack of detectable uptake by cells. Science (1966) 1.09
An experimental approach to virus myocarditis. Prog Med Virol (1965) 1.09
Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun (1976) 1.09
A new continuing fatigue syndrome following mild viral illness. A proscription to exercise. Chest (1988) 1.08
Interferon and interferon inducers in the treatment of malignancies. Arch Intern Med (1970) 1.08
Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans. J Infect Dis (1976) 1.07
Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J Infect Dis (1979) 1.07
Fatal syncytial virus pneumonia in a laminar airflow room. JAMA (1981) 1.05
Theophylline-induced seizures: clinical and pathophysiologic aspects. West J Med (1983) 1.05
Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun (1979) 1.05
Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother (1995) 1.04
Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis. Antimicrob Agents Chemother (1981) 1.04
Mycotic aneurysm and endocarditis. Two uncommon complications of salmonella infection in the same patient. Am J Cardiol (1966) 1.04
Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. Science (1977) 1.03
The classic bacterial pneumonias. Dis Mon (1975) 1.03
Lack of correlation between interferon induction and antitumour effect of poly I-poly C. Nat New Biol (1971) 1.02
Complement-requiring neutralizing antibodies in Herpesvirus hominis encephalitis. J Immunol (1970) 1.02
Enterovirus hemagglutination: inhibition by several enzymes and sugars. J Immunol (1965) 1.02
Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res (1979) 1.01
Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex. Antimicrob Agents Chemother (1977) 1.01
A mouse model of dilated-type cardiomyopathy due to coxsackievirus B3. J Infect Dis (1981) 1.01
Comparative analysis of three antifungal susceptibility test methods against prospectively collected Candida species. Diagn Microbiol Infect Dis (1994) 1.01
Synergy of 9-beta-D-arabinofuranosyladenine and human interferon against Herpes simplex virus, type 1. J Infect Dis (1974) 1.00
Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep (1978) 1.00
Herpesvirus hominis encephalitis. Neurological manifestations and use of idoxuridine. Arch Neurol (1970) 1.00
A preliminary trial of poly(I,C)-LC in multiple sclerosis. J Biol Response Mod (1985) 0.99
Serologic responses to herpes simplex virus in rabbits: complement-requiring neutralizing, conventional neutralizing, and passive hemagglutinating antibodies. J Infect Dis (1974) 0.99
Postinfectious encephalopathy after treatment of herpes simplex encephalitis with acyclovir. Pediatr Infect Dis (1984) 0.99
Virus myopericarditis. Ann Intern Med (1968) 0.99
Pseudomonas cepacia peritonitis associated with contamination of automatic peritoneal dialysis machines. Ann Intern Med (1982) 0.98
Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.98
The effect of interferon, interferon inducers or interferon induced virus resistance on subsequent interferon production. J Gen Virol (1972) 0.97
Non-traumatic gram-negative bacillary meningitis in the Detroit Medical Center, 1964-1974; (with special mention of cases due to Escherichia coli). Medicine (Baltimore) (1978) 0.97
Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis (1979) 0.97
Gentamicin in treatment of primary Gram-negative pneumonias. Am J Med Sci (1970) 0.96
Cellular interactions of several enteroviruses and a reovirus after treatment with sodium borohydride or carbohydrases. Virology (1968) 0.96
Induction of interferon in lymphoblastoid cell lines. Proc Soc Exp Biol Med (1970) 0.96
Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas. J Infect Dis (1980) 0.96
Outbreak of pseudomonas paucimobilis in an intensive care facility. JAMA (1981) 0.96
Interferon. Annu Rev Microbiol (1966) 0.95
Mechanisms of DEAE-dextran enhancement of polynucleotide induction of interferon. Proc Soc Exp Biol Med (1971) 0.94
Some previously unrecognized features of herpes simplex virus encephalitis. Neurology (1978) 0.94
Characteristics and sequelae of paregoric abuse. Ann Intern Med (1966) 0.93
Enterovirus hemagglutination: inhibition by aldoses and a possible mechanism. J Immunol (1966) 0.92
Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination. J Clin Invest (1978) 0.92
Legionella feeleii-associated pneumonia in humans. Am J Clin Pathol (1986) 0.91
Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinic-polyribocytidylic acid-poly-L-lysine. J Infect Dis (1976) 0.91
Studies on poly I:C toxicity in experimental animals. Toxicol Appl Pharmacol (1972) 0.90